MDxHealth (NASDAQ:MDXH) Releases Quarterly Earnings Results, Beats Expectations By $999.13 EPS

MDxHealth (NASDAQ:MDXH) released its quarterly earnings data on Thursday. The company reported $999.00 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $999.13, reports. MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. The company had revenue of $29.55 million during the quarter, compared to analyst estimates of $26.05 million.

Here are the key takeaways from MDxHealth’s conference call:

• Q4 billable volume was ~38,000 tests (up 62% YoY) with liquid tests up 128%, full-year revenue reported at $107.9M, and 2026 guidance implies roughly 28% growth to $137–$140M driven by unit growth rather than price.
• MDxHealth completed the Q4 transition of Select mdx customers to ExoDx, expects the ExoDx business to contribute $20M+ in 2026, and plans cross-selling after sales integration finishes in Q1.
• Short-term financial pressure: Q4 operating loss rose to $5.3M and net loss to $8.9M, adjusted EBITDA was -$2.1M, and cash on hand was $29M, with management attributing the weakness to integration-related OpEx.
• MDxHealth negotiated an amendment with Exact Sciences that lowers the upcoming earn-out by about $20M and defers full payment by a year, improving near-term liquidity and flexibility.
• Clinical progress: the GPS ProMPT study is complete and the landmark GPS‑ProtecT trial is commencing, which management says could support NCCN guideline adoption and strengthen long-term test adoption.

MDxHealth Stock Up 0.6%

MDXH stock traded up $0.02 during mid-day trading on Thursday, reaching $3.55. 343,591 shares of the company traded hands, compared to its average volume of 88,357. The firm’s 50 day moving average price is $3.54 and its 200 day moving average price is $3.75. The stock has a market cap of $175.73 million, a price-to-earnings ratio of -5.55 and a beta of 1.64. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $5.33.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its position in shares of MDxHealth by 220.0% during the fourth quarter. XTX Topco Ltd now owns 40,860 shares of the company’s stock valued at $146,000 after buying an additional 28,090 shares during the last quarter. Millennium Management LLC lifted its stake in MDxHealth by 328.3% during the 4th quarter. Millennium Management LLC now owns 116,831 shares of the company’s stock valued at $417,000 after acquiring an additional 89,553 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in MDxHealth during the 4th quarter worth $68,000. 683 Capital Management LLC bought a new stake in shares of MDxHealth in the 4th quarter worth $384,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of MDxHealth in the fourth quarter valued at about $83,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on MDXH shares. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. BTIG Research restated a “buy” rating and issued a $7.00 target price on shares of MDxHealth in a research note on Tuesday, December 23rd. TD Cowen upped their price target on MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Lake Street Capital increased their price target on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.75.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.